The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.

@article{Bulteel2014TheEO,
  title={The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.},
  author={Naomi Bulteel and Loveleen Bansi-Matharu and Duncan Churchill and David Dunn and David Bibby and Teresa A. Garrett Hill and Caroline Sabin and David D. Nelson},
  journal={The Journal of infection},
  year={2014},
  volume={68 1},
  pages={
          77-84
        }
}
BACKGROUND Lamivudine (3TC) and emtricitabine (FTC) are guideline choices for combination highly active antiretroviral therapy (HAART). 3TC has a shorter intracellular half life than FTC and may be more likely to lead to the development of drug resistant HIV variants. METHODS In this study we analysed linked data from the observational UK Collaborative HIV Cohort (CHIC) Study and UK HIV Drug Resistance Database (HDRD) to investigate the rate of development of K65R or M184V resistance… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Similar Papers

Loading similar papers…